Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01612377
• Other study ID #: Z102-009
• Status: Terminated
• Phase: Phase 2
• First received: February 22, 2012
• Last updated: September 10, 2012
• Start date: March 2012
• Est. completion date: September 2013

Study information

• Verified date: September 2012
• Source: Zalicus
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to severe Rheumatoid Arthritis for a period of 52 weeks.

Description:

This is a long-term Phase II safety study of approximately 52 weeks in duration. Eligible patients will have completed at least 6 weeks of Protocol Z102-008 and will have met all inclusion and exclusion criteria for this study.

All patients will be up-titrated on Z102 over 3 weeks or will receive prednisone 5.0 mg or 7.5 mg:

Primary objectives:

• Adverse events (AEs)

• Vital signs

• Clinical laboratory and clinical chemistry evaluations

Secondary objectives:

• Joint imaging and bone density

• DAS28-CRP and individual components

• Patient Global Assessment of Disease Activity

• American College of Rheumatology criteria (ACR 20, ACR 50, ACR 70)

• Multidimensional Assessment of Fatigue (MAF)

• Time to failure

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: September 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have completed all 12 weeks of Protocol Z102-008 or discontinued after participating in at least 6 weeks of the randomized withdrawal portion of Z102-008 for acceptable reasons

• Have met all inclusion/exclusion criteria for enrollment into Protocol Z102-008

• Have been on DMARD therapy for at least 90 days and have been on a stable DMARD dose without dosage adjustment or modification for 6 weeks prior to enrollment into Protocol Z102-008, and be able to maintain the same dose of conventional DMARD therapy during Protocol Z102-009 participation

Exclusion Criteria:

• Did not complete 6 weeks of the double-blind section of Protocol Z102-008, or was discontinued from Protocol Z102-008 for reasons of an AE, protocol violation, or non-compliance

• Active cardiovascular disease, unless well controlled by appropriate treatment, for a minimum of 3 months prior to screening for enrollment into Protocol Z102-008

• Currently taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg

• Taking oral steroids at a daily prednisone dose, or the equivalent, of >10 mg/day within the past 2 weeks

• Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering study Protocol Z102-008 or Protocol Z102-009, at any time during the study, or be anticipated to be given at any time during the study

• The need to continue the use of one or multiple NSAIDs at the same time, or use acetaminophen on a chronic basis

• All opiate use is prohibited.

• Use of any other medications or herbs or non-pharmacological treatments (e.g., acupuncture) used for the treatment of pain is prohibited

• Has, or has had, any active severe infections or recent invasive surgical procedures within 30 days of Protocol Z102-008 or Protocol Z102-009 initiation

• HIV, hepatitis B, or hepatitis C infection

• Has undergone administration of any investigational drug within 30 days of study

• All biologic agents are excluded for 90 days prior to Screening and during the conduct of Protocol Z102-008, and Protocol Z102-009

• Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of Protocol Z102-008 Screening or Protocol Z102-009 initiation, or at any time during participation in study Protocol Z102-008

• Has a history of hypersensitivity reaction to glucocorticoids and/or dipyridamole

• Known or suspected history of alcohol or drug abuse within 2 years prior to Screening for Protocol Z102-008

• Has any other medical condition which may interfere with the conduct of this study in the opinion of the investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Prednisolone-Dipyridamole
Oral, QD
• Prednisone
Oral QD Prednisone 5mg
• prednisone
Oral, QD prednisone 7.5mg

Locations

Country	Name	City	State
Serbia	Nemanja Damjanov	Belgrade

Sponsors (1)

Lead Sponsor	Collaborator
Zalicus

Country where clinical trial is conducted

Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in incidence rates of adverse events between treament groups		12 months	No
Secondary	Joint imaging		12 months	No